



# *Victory over Vitis in Vancouver*



## 2026 Congress Program

AUGUST 14-16, 2026  
HYATT REGENCY VANCOUVER  
VANCOUVER, CANADA

[www.VitiligoCongress.org](http://www.VitiligoCongress.org)

## WELCOME TO VANCOUVER

### 7TH VITILIGO INTERNATIONAL CONGRESS

**AUGUST 14-16, 2026**

**Hyatt Regency Vancouver | Vancouver, BC, Canada**

This activity is brought to you in collaboration with the GVF (Global Vitiligo Foundation)



#### CONGRESS HIGHLIGHTS INCLUDE:

- Scientific abstracts on translational research, artificial intelligence, surgical treatment, epidemiology, phototherapy, and assessment of vitiligo severity, impact & therapeutic response
- Interactive question and answer sessions
- Presentations from renowned international vitiligo healthcare leaders
- Poster Presentations
- Networking opportunities among clinicians and scientists across institutions and geographical borders



## TABLE OF CONTENTS

|                                     |           |
|-------------------------------------|-----------|
| <b>Welcome From VIC7 Co-Chairs</b>  | <b>4</b>  |
| <b>Congress Committees</b>          | <b>5</b>  |
| <b>General Congress Information</b> | <b>6</b>  |
| <b>Social Gatherings</b>            | <b>7</b>  |
| <b>Satellite Symposium</b>          | <b>7</b>  |
| <b>Sponsor Acknowledgement</b>      | <b>8</b>  |
| <b>Keynote Presentations</b>        | <b>9</b>  |
| <b>Program at a Glance</b>          | <b>10</b> |
| <b>Detailed Program</b>             | <b>12</b> |
| <b>Poster Listing</b>               | <b>19</b> |
| <b>Sponsor Profiles</b>             | <b>22</b> |

## WELCOME FROM VIC7 CO-CHAIRS

Dear Colleagues,

On behalf of the 7th Vitiligo International Congress Organizing Committee, it is our great pleasure to welcome you to the 7th Vitiligo International Congress (VIC7) in Vancouver, British Columbia, Canada.

We are truly excited to share this year's educational program with you. It brings together a diverse, international faculty and offers a rich blend of cutting-edge science, clinical insights, and interactive discussions. From the latest research advances to practical approaches in patient care, we hope the program will inspire meaningful dialogue and new collaborations across our global community.

We are equally delighted to host you in Vancouver—a vibrant, welcoming city known for its multiculturalism, inspiring landscapes, history, and cuisine. We encourage you to take time to experience our city while connecting with colleagues from around the world.

We hope your time at VIC7 will be both memorable and engaging, and we thank you for being part of this important gathering.



**Dr. Harvey Lui, MD, FRCPC**  
Co-Chair, VIC7



**Dr. Sunil Kalia, MD, MHSc, FAAD, FRCPC**  
Co-Chair, VIC7

## CONGRESS COMMITTEES

### ORGANIZING COMMITTEE

#### CO-CHAIRS:

Harvey Lui, MD, FRCPC | Canada

Sunil Kalia, MD, MHSc, FAAD, FRCPC | Canada

Tashmeeta Ahad, BM BCh, MA(Cantab),  
MRCP(UK)(Derm) | Canada

Seemal Desai, MD, FAAD | USA

Iltefat Hamzavi, MD, FAAD | USA

Youwen Zhou, MD, PhD, FRCPC, FAAD | Canada

### SCIENTIFIC PROGRAM REVIEW COMMITTEE

#### CO-CHAIRS:

Iltefat Hamzavi, MD, FAAD | USA

Youwen Zhou, MD, PhD, FRCPC, FAAD | Canada

Marwa Abdallah, MD | Egypt

Tashmeeta Ahad, BM BCh, MA(Cantab),  
MRCP(UK)(Derm) | Canada

Ammar Ahmed, MD, FAAD | USA

Maggi Ahmed, MD, PhD | USA

Jung Min Bae, MD, PhD | South Korea

Reetesh Bose, MD, FRCPC | Canada

Nada Elbuluk, MD, MSc, FAAD | USA

Samia Esmat, MD | Egypt

Deepti Ghia, MD, DNB, FCPS, DDV | India

Victor Huang, MD, FAAD | USA

Richard Huggins, MD | USA



Sunil Kalia, MD, MHSc, FAAD, FRCPC | Canada

Harvey Lui, MD, FRCPC | Canada

Yvette Miller-Monthrope, MD, MScCH, FRCPC |  
Canada

Tasneem F. Mohammad, MD, FAAD | USA

Davinder Parsad, MD | India

Thierry Passeron, MD, PhD | France

Julien Ringuet, MD, MSc, FRCPC | Canada

David Rosmarin, MD | USA

Julien Senschal, MD, PhD | France

Nanja van Geel, MD, PhD | Belgium

Albert Wolkerstorfer, MD, PhD | Netherlands

### GLOBAL VITILIGO FOUNDATION

400 Winding Creek Blvd  
Mechanicsburg, PA 17050 USA

Phone: +1.866.777.1277

[www.globalvitiligofoundation.org](http://www.globalvitiligofoundation.org)

Executive Director: Catherine Johannesen, CAE

[info@globalvitiligofoundation.org](mailto:info@globalvitiligofoundation.org)



## GENERAL CONGRESS INFORMATION

### CONGRESS NAME BADGE

Your official congress name badge must be worn at all times to gain and maintain access to all VIC7 activities. Please Note: Some activities require preregistration/prepaid tickets (VIC7 Closing Dinner) or are by invitation only.

### CONGRESS MEALS

Breakfast, breaks and lunch will be provided in **Regency AB**

Saturday, August 15 lunch; **Regency D**.  
A hot plated lunch will be served during Incyte's Satellite Symposium. Seating is based on first available and is open to HCP's, on a priority basis, then sponsors.

### REGISTRATION DESK

**Regency Foyer (3rd Floor)**

#### Hours

Thursday, August 13 | 12:00 – 18:00

Friday, August 14 | 07:00 – 18:00

Saturday, August 15 | 07:00 – 18:00

### SPEAKER CENTRE

The Speaker Centre is located in the **Oxford Room (3rd Floor)**. PowerPoint presentations must be brought to the Speaker Centre no later than five (5) hours prior to your session time & during Speaker Centre hours.

#### Hours

Thursday, August 13 | 12:00 – 18:00

Friday, August 14 | 07:00 – 18:00

Saturday, August 15 | 07:00 – 15:00



At Abbvie, we're committed to investing in science, and innovating for patients. Striving to give dermatology patients the opportunity to feel free in their own skin.

abbvie

ALL-ABBV-260259



## SOCIAL GATHERINGS

We look forward to attendees participating in the VIC7 social gatherings, where participants will be able to network with colleagues and create new connections and opportunities for collaboration.

### **Congress Welcome Reception**

**Friday, August 15 | 18:00 – 20:00**

***Perspectives Level, 34th Floor***

Complimentary for VIC7 registered congress participants

### **VIC7 Closing Dinner**

**Saturday, August 15 | 18:30 – 21:00**

***Prince of Wales***

Cocktail Attire

Pre-paid Ticket Required. Limited availability. Please check at the registration desk if you have not purchased a ticket.

## SATELLITE SYMPOSIUM

**SATURDAY, AUGUST 15, 2026 | 12:00 – 13:00**

*Lunch will be served during symposium*

***Regency D***

*Sponsored by Incyte*



**Advancing Nonsegmental Vitiligo Care:  
Current Treatment Paradigms, Emerging  
Therapies, and Case-Based Clinical Insights**

### **PRESENTERS:**

**Pearl E. Grimes, MD, FAAD** | Los Angeles, CA, USA

**Vimal H. Prajapati, MD, FRCPC, DABD** | Calgary, AB, Canada

### **Symposium Learning Objectives:**

1. Provide a comprehensive overview of the evolving vitiligo treatment paradigm, incorporating current guidelines and key evidence for available treatments
2. Evaluate emerging pipeline therapies and their potential impact on clinical practice
3. Explore practical case-based insights to inform treatment decision-making amid a rapidly advancing therapeutic landscape

**WIFI**

**NETWORK: HYATT\_MEETING**

**PW: 2026VIC**

## SPONSOR ACKNOWLEDGEMENT

*The 7th Vitiligo International Congress acknowledges  
the generous support of the following organizations:*

### DIAMOND SPONSOR



### SILVER SPONSORS



### BRONZE SPONSORS



## KEYNOTE PRESENTATIONS

## SESSION 2: KEYNOTE PRESENTATION

## MEGAN K. LEVINGS, PHD

Regulatory T cells (Tregs) prevent autoimmunity through a variety of immunosuppressive mechanisms. Harnessing their natural properties is a promising approach to develop new therapies which induce immune tolerance rather than broad spectrum immunosuppression. The presentation will summarize the biology and mechanisms of action of Tregs, discuss the development and clinical testing of engineered Treg cell therapies and the interaction between different types of immunosuppression and tolerance induction.



## Megan K. Levings, PhD

*Professor, Department of Surgery and School of Biomedical Engineering, UBC  
Investigator, BC Children's Hospital Research Institute, Vancouver, Canada*

## Regulatory T cells to induce immune tolerance

Friday, August 14 | 12:45 – 13:25 | *Regency C (3rd Floor)*

## SESSION 8: KEYNOTE PRESENTATION

## AHMED M. ALISSA, MD, FRCPC

Vitiligo is a chronic autoimmune depigmenting disorder affecting approximately 1–2% of the population, with significant quality-of-life implications. Despite its prevalence, management remains challenging due to disease heterogeneity, variability in treatment response, and the need to integrate both medical and surgical modalities. Recent advances in understanding the immunopathogenesis of vitiligo — particularly the role of CD8+ T cells, IFN- $\gamma$  signaling, and the JAK-STAT pathway — have opened new therapeutic frontiers that are reshaping clinical practice.



## Ahmed M. Alissa, MD, FRCPC

*Consultant Dermatologist, Ovalia Clinic  
Consultant Dermatologist, Derma Clinic  
Riyadh, Saudi Arabia*

## Comprehensive Medical and Surgical Care of Vitiligo: An Integrated Approach

Saturday, August 15 | 13:05 – 13:45 | *Regency C (3rd Floor)*

## PROGRAM AT A GLANCE

### PRE CONGRESS DAY – Thursday, August 13, 2026

|               |                                                     |                        |
|---------------|-----------------------------------------------------|------------------------|
| 12:00 – 17:00 | Registration                                        | <i>Regency Foyer</i>   |
| 12:00 – 18:00 | Speaker Centre                                      | <i>Oxford</i>          |
| 17:30 – 20:30 | <b>Faculty &amp; Sponsor Dinner</b> (by invitation) | <i>Prince of Wales</i> |

### DAY ONE – Friday, August 14, 2026

|               |                                            |                                        |
|---------------|--------------------------------------------|----------------------------------------|
| 07:00 – 18:00 | Registration / Speaker Centre              | <i>Regency Foyer / Oxford</i>          |
| 07:30 – 08:45 | Breakfast / Exhibits / Posters             | <i>Regency AB</i>                      |
| 07:30 – 17:00 | Exhibits Open                              | <i>Regency AB</i>                      |
| 08:45 – 09:00 | <b>Welcome, Opening Remarks</b>            | <i>Regency C</i>                       |
| 09:00 – 09:40 | <b>Rapid Fire, Best of Posters</b>         | <i>Regency C</i>                       |
| 09:45 – 11:35 | <b>Session 1 – Translational Research</b>  | <i>Regency C</i>                       |
| 11:40 – 12:40 | Lunch / Exhibits / Posters                 | <i>Regency AB</i>                      |
| 12:45 – 13:25 | <b>Session 2, Keynote Presentation</b>     | <i>Regency C</i>                       |
| 13:30 – 15:30 | <b>Session 3 – Medical Treatment</b>       | <i>Regency C</i>                       |
| 15:30 – 16:00 | Coffee Break / Exhibits / Posters          | <i>Regency AB</i>                      |
| 16:00 – 17:00 | <b>Session 4 – Artificial Intelligence</b> | <i>Regency C</i>                       |
| 17:05 – 17:55 | <b>Session 5 – Epidemiology</b>            | <i>Regency C</i>                       |
| 18:00 – 20:00 | <b>Welcome Reception</b>                   | <i>Perspectives Level (34th Floor)</i> |

### DAY TWO – Saturday, August 15, 2026

|               |                                                                                       |                      |
|---------------|---------------------------------------------------------------------------------------|----------------------|
| 07:00 – 18:00 | Registration                                                                          | <i>Regency Foyer</i> |
| 07:00 – 15:00 | Speaker Centre                                                                        | <i>Oxford</i>        |
| 07:00 – 08:00 | Breakfast / Exhibits / Posters                                                        | <i>Regency AB</i>    |
| 07:00 – 16:30 | Exhibits Open                                                                         | <i>Regency AB</i>    |
| 08:00 – 09:00 | <b>Global Vitiligo Foundation Session</b>                                             | <i>Regency C</i>     |
| 09:10 – 10:10 | <b>Session 6 – Surgical Treatment</b>                                                 | <i>Regency C</i>     |
| 10:15 – 11:55 | <b>Session 7 – Basic Science</b>                                                      | <i>Regency C</i>     |
| 12:00 – 13:00 | <b>Satellite Symposium, sponsored by Incyte</b> (lunch served)                        | <i>Regency D</i>     |
| 13:05 – 13:45 | <b>Session 8, Keynote Presentation</b>                                                | <i>Regency C</i>     |
| 13:50 – 15:50 | <b>Session 9 – Assessment of Vitiligo Severity, Impact &amp; Therapeutic Response</b> | <i>Regency C</i>     |
| 15:50 – 16:20 | Coffee Break / Exhibits / Posters                                                     | <i>Regency AB</i>    |

|               |                                                         |                        |
|---------------|---------------------------------------------------------|------------------------|
| 16:20 – 17:40 | <b>Session 10 – Phototherapy &amp; Case Reports</b>     | <i>Regency C</i>       |
| 17:40 – 18:00 | <b>Closing Comment</b>                                  | <i>Regency C</i>       |
| 18:30 – 21:00 | <b>VIC7 Closing Dinner</b><br>(prepaid ticket required) | <i>Prince of Wales</i> |

**DAY THREE – Sunday, August 16, 2026**

|               |                                                     |                      |
|---------------|-----------------------------------------------------|----------------------|
| 07:30 – 09:00 | Breakfast                                           | <i>Regency Foyer</i> |
| 09:00 – 12:00 | <b>Pfizer Canada Advisory Board</b> (by invitation) | <i>Balmoral</i>      |



## DETAILED PROGRAM

*As of the date of printing*

|                                                                                     |               |                                                                                                                                                                 |
|-------------------------------------------------------------------------------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Thursday   August 13, 2026                                                          | 12:00 – 17:00 | <b>REGISTRATION OPEN</b><br><i>Regency Foyer</i>                                                                                                                |
|                                                                                     | 12:00 – 18:00 | <b>SPEAKER CENTRE OPEN</b><br><i>Oxford Room</i>                                                                                                                |
|                                                                                     | 17:30 – 20:30 | <b>Faculty &amp; Sponsor Dinner</b> [by invitation]<br><i>Prince of Wales Room</i>                                                                              |
|  |               |                                                                                                                                                                 |
| Friday   August 14, 2026                                                            | 07:00 – 18:00 | <b>REGISTRATION &amp; SPEAKER CENTRE OPEN</b><br><i>Regency Foyer &amp; Oxford Room</i>                                                                         |
|                                                                                     | 07:30 – 08:45 | <b>BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL</b><br><i>Regency AB</i>                                                                                        |
|                                                                                     | 07:30 – 17:00 | <b>EXHIBITS OPEN</b><br><i>Regency AB</i>                                                                                                                       |
|                                                                                     | 08:45 – 09:00 | <b>Welcome &amp; Opening Remarks</b><br><i>Regency C</i>                                                                                                        |
|                                                                                     | 09:00 – 09:40 | <b>Rapid Fire, Best of Posters</b><br><i>Regency C</i><br>Chair: Iltefat Hamzavi                                                                                |
|                                                                                     | 09:00         | Introduction – Iltefat Hamzavi                                                                                                                                  |
|                                                                                     | 09:05         | Real-World Psychosocial Burden, Quality of Life, and Disease Management of Non-Segmental Vitiligo in the United States - <b>Samantha Kurosky, New York, USA</b> |

# Friday | August 14, 2026

|                      |                                                                                                                                                                                                             |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09:07                | Development and validation of an Arabic vitiligo impact patient scale short form version - <b>Mona Atwa, Ismailia, Egypt</b>                                                                                |
| 09:09                | Mannose-Binding Lectin Gene Polymorphism in Vitiligo: an Observational Study and Computational Analysis - <b>Noha Tawfik, Ismaila, Egypt</b>                                                                |
| 09:11                | Assessment of Vitiligo Activity before and after Alexandrite and Nd:YAG Laser Assisted Hair Removal in Patients with Stable Non Segmental Vitiligo - <b>Mona Atwa, Ismailia, Egypt</b>                      |
| 09:13                | Do Surgical Implants Trigger Autoimmune Depigmentation? A Global Study of Orthopedic and Breast Prostheses - <b>Racha Cherradi, Houston, USA</b>                                                            |
| 09:15                | The efficacy of Topical barcitinib and excimer light in non segmental vitiligo – <b>Yasmin Elbadrmany, Assuit, Egypt</b>                                                                                    |
| 09:17                | Extended Phototherapy Sessions and Their Effect on Serum Beta-Endorphin and Well-Being in Vitiligo Patients – <b>Wedad Z. Mostafa, Cairo, Egypt</b>                                                         |
| 09:19                | Autofluorescence Biomarkers of Vitiligo Detected by Non-invasive in vivo Excitation-Emission Matrix Spectroscopy – <b>Jianhua Zhao, Vancouver, Canada</b>                                                   |
| 09:21                | The role of mini-oral pulse steroid therapy in melanocyte keratinocyte transplantation: A randomized controlled trial – <b>Sherouk Ellessawy, Cairo, Egypt</b>                                              |
| 09:23                | Cadaver-Based Simulation for Comprehensive Hands-on Training in Vitiligo Surgery: A High-Volume Scalable Model – <b>Deepti Ghia, Mumbai, India</b>                                                          |
| 09:25                | Application of Exposure-Response Modeling to Inform the Phase 3 Dose Selection of Povorcitinib in Nonsegmental Vitiligo – <b>Jessica Wojciechowski, Wilmington, USA</b>                                     |
| 09:27                | Q&A                                                                                                                                                                                                         |
| <b>09:45 – 11:35</b> | <b>Session 1 – Translational Research</b><br><b>Regency C</b><br>Chair: Harvey Lui                                                                                                                          |
| 09:45                | Introduction – Harvey Lui                                                                                                                                                                                   |
| 09:50                | Quantitative Assessment of Biophysical Skin Properties in Vitiligo Using in vivo Multimodal Spectroscopy Reveals Significant Tissue Alterations Beyond Melanopenia – <b>Jianhua Zhao, Vancouver, Canada</b> |
| 10:00                | Cellular and Immune Landscapes of vitiligo: Insights from Genomic and Transcriptomic Analyses - <b>Hyun Jeong Ju, Seoul, Korea</b>                                                                          |
| 10:10                | Metabolic Reprogramming of Keratinocytes as a Driver of Therapy Resistance in Acral Vitiligo – <b>Jin Cheol Kim, Suwon, Korea</b>                                                                           |
| 10:20                | Decoding Vitiligo through Sebum: A possible novel platform for disease monitoring – <b>Mauro Picardo, Rome, Italy</b>                                                                                       |
| 10:30                | Towards understanding tissue factors that determine heterogenous vitiligo response to JAK inhibitor treatment – <b>Elizabeth Vazquez, Irvine, USA</b>                                                       |
| 10:40                | Upadacitinib Suppresses Inflammatory Pathways and Enhances Melanocyte-Associated Biomarker c-Kit in Non-Segmental Vitiligo: Phase 3 Biomarker Analysis – <b>Anand Ganesan, Irvine, USA</b>                  |
| 10:50                | Enhancing Visualization of Vitiligo Lesions in Clinical Images Using Yellow Channel Suppression – <b>James Zhong, Burnaby, Canada</b>                                                                       |

|                      |                                                                                                                                                                                                                      |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11:00                | hiJAcK vitiligo: JAK3 and TEC-family kinase inhibition in the pathogenesis and treatment of vitiligo – <b>Sanne Uitentuis, Amsterdam, Netherlands</b>                                                                |
| 11:10                | Methodological approaches to Clinical Practice Outcomes for vitiligo – <b>Invited Speaker: Albert Wolkerstorfer, Amsterdam, Netherlands</b>                                                                          |
| 11:30                | Q&A                                                                                                                                                                                                                  |
| <b>11:40 – 12:40</b> | <b>LUNCH AND POSTER VIEWING IN EXHIBIT HALL</b><br><b>Regency AB</b>                                                                                                                                                 |
| <b>12:45 – 13:25</b> | <b>Session 2 – Keynote Presentation: Megan K. Levings, PhD</b><br><b>Regency C</b><br>Chair: Sunil Kalia                                                                                                             |
| 12:45                | Introduction – Sunil Kalia                                                                                                                                                                                           |
| 12:50                | T cells to induce immune tolerance – <b>Megan K. Levings, Vancouver, Canada</b>                                                                                                                                      |
| 13:20                | Q&A                                                                                                                                                                                                                  |
| <b>13:30 – 15:30</b> | <b>Session 3 – Medical Treatment</b><br><b>Regency C</b><br>Chair: Youwen Zhou                                                                                                                                       |
| 13:30                | Introduction – Youwen Zhou                                                                                                                                                                                           |
| 13:35                | Combination Therapy in Vitiligo – <b>Invited Speaker: Samia Esmat, Cairo, Egypt</b>                                                                                                                                  |
| 13:55                | Identifying Unmet Needs in Patients with Non-Segmental Vitiligo - a Survey Study in Egypt, South-Korea and the Netherlands – <b>Marlide Jukema, Amsterdam, Netherlands</b>                                           |
| 14:05                | Efficacy of Upadacitinib in Adults and Adolescents for Treatment of Nonsegmental Vitiligo in Six Body Regions Across 48 Weeks of Treatment from Two Phase 3 Studies (Viti-Up) – <b>Iltefat Hamzavi, Detroit, USA</b> |
| 14:15                | Circulating Central Memory T Cells in Localized Non-Segmental Vitiligo with special emphasis on the additive value early of systemic treatment – <b>Rania Mogawer, Cairo, Egypt</b>                                  |
| 14:25                | Post-Stability Maintenance Strategies and Recurrence Risk in Nonsegmental Vitiligo: A Multicenter Real-World Cohort Study – <b>Chau Yee Ng, Taoyuan, Taiwan</b>                                                      |
| 14:35                | Association Between Repigmentation Response and Geographic Latitude Among Patients With Vitiligo – <b>Grace Wong, Toronto, Canada</b>                                                                                |
| 14:45                | Topical travoprost In combination with 308 nm excimer light and fractional carbon dioxide laser in the treatment of resistant vitiligo patches – <b>Yasmin Elbadrmany, Assuit, Egypt</b>                             |
| 14:55                | Efficacy of Upadacitinib in Adults and Adolescents for Treatment of Nonsegmental Vitiligo: Subgroup Analysis at 48 Weeks of Treatment From Two Phase 3 Studies (Viti-Up) – <b>Chih-ho Hong, Vancouver, Canada</b>    |
| 15:05                | Open-Label Multi-Center Randomized Controlled Trial Comparing Topical Ruxolitinib 1.5% Cream with Topical Tacrolimus 0.1% Ointment in Non-Segmental Vitiligo – <b>Ahmed Mourad, Cairo, Egypt</b>                     |

# Friday | August 14, 2026

|                      |                                                                                                                                                                                        |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15:15                | Clinical pearls in the use of monobenzyl ether of hydroquinone for depigmentation in cases of extensive vitiligo: A retrospective study – <b>Ahmed Alissa, Riyadh, Saudi Arabia</b>    |
| 15:25                | Q&A                                                                                                                                                                                    |
| <b>15:30-16:00</b>   | <b>BREAK AND POSTER VIEWING IN EXHIBIT HALL</b><br><b>Regency AB</b>                                                                                                                   |
| <b>16:00 – 17:00</b> | <b>Session 4 – Artificial Intelligence in Vitiligo</b><br><b>Regency C</b><br>Chair: Sheila Wang                                                                                       |
| 16:00                | Introduction – Sheila Wang                                                                                                                                                             |
| 16:05                | Artificial Intelligence – Derived VASI and Point of Care Tracking in Vitiligo – <b>Invited Speaker: Sheila Wang, Toronto, Canada</b>                                                   |
| 16:25                | AI-based Semi-automatic Segmentation for Global View Vitiligo Lesion Assessment – <b>Yuheng Wang, Vancouver, Canada</b>                                                                |
| 16:35                | Artificial Intelligence – Assisted Cellular-Resolution Optical Coherence Tomography for In Vivo Characterization of Disease Activity in Vitiligo – <b>Chau Yee Ng, Taoyuan, Taiwan</b> |
| 16:45                | Artificial Intelligence-Derived VASI for Point-of-Care Vitiligo Assessment: A Proof-of-Concept Validation Study – <b>Tahirih Nasser, Toronto, Canada</b>                               |
| 16:55                | Q&A                                                                                                                                                                                    |
| <b>17:05 – 17:55</b> | <b>Session 5 – Epidemiology</b><br><b>Regency C</b><br>Chair: Tashmeeta Ahad                                                                                                           |
| 17:05                | Introduction – Tashmeeta Ahad                                                                                                                                                          |
| 17:10                | Updates on the Global Burden of Disease – <b>Invited Speaker: Iltefat Hamzavi, Detroit, USA</b>                                                                                        |
| 17:30                | Rethinking Skin Cancer Risk in Vitiligo: Evidence from a Meta-analysis, and Clinical Observations – <b>Sanne Uitentuis, Amsterdam, Netherlands</b>                                     |
| 17:40                | Alopecia Areata in Vitiligo: Prevalence and Clinical Risk Factors in a Moroccan Cohort – <b>Laila Benzekri, Rabat, Morocco</b>                                                         |
| 17:50                | Q&A                                                                                                                                                                                    |
| <b>18:00 – 20:00</b> | <b>WELCOME RECEPTION</b><br><b>Perspectives Level, 34<sup>th</sup> Floor</b>                                                                                                           |

**Saturday | August 15, 2026**

|               |                                                                                                                                                                                           |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 07:00 – 18:00 | <b>REGISTRATION OPEN</b><br><i>Regency Foyer</i>                                                                                                                                          |
| 07:00 – 15:00 | <b>SPEAKER CENTRE OPEN</b><br><i>Oxford Room</i>                                                                                                                                          |
| 07:00 – 08:00 | <b>BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL</b><br><i>Regency AB</i>                                                                                                                  |
| 07:00 – 16:30 | <b>EXHIBITS OPEN</b><br><i>Regency AB</i>                                                                                                                                                 |
| 08:00 – 09:00 | <b>Global Vitiligo Foundation Session</b><br><i>Regency C</i>                                                                                                                             |
| 09:10 – 10:10 | <b>Session 6 – Surgical Treatment</b><br><i>Regency C</i><br>Chair: Sunil Kalia                                                                                                           |
| 09:10         | Introduction – Sunil Kalia                                                                                                                                                                |
| 09:15         | Vitiligo Surgery Through the Years: From Tissue Transfer to Cellular Restoration – <b>Invited Speaker: Davinder Parsad, Chandigarh, India</b>                                             |
| 09:35         | Residual Cytotoxic Immune Activity Predicts Repigmentation Outcomes After Suction Blister Epidermal Grafting in Stable Vitiligo – <b>Chau Yee Ng, Taoyuan, Taiwan</b>                     |
| 09:45         | Efficacy of Skin Micrograft Suspension prepared by tissue lyser versus cryolysis using liquid nitrogen in The Treatment of Stable Resistant Vitiligo – <b>Lamia Elgarhy, Tanta, Egypt</b> |
| 09:55         | Efficacy and Long-Term Outcomes of Noncultured Epidermal Cell Suspension Grafting using Suction Blisters as Donor Tissue – <b>Salma Villeda-Flores, Monterrey, Mexico</b>                 |
| 10:05         | Q&A                                                                                                                                                                                       |
| 10:15 – 11:55 | <b>Session 7 – Basic Science</b><br><i>Regency C</i><br>Chair: Seemal Desai                                                                                                               |
| 10:15         | Introduction – Seemal Desai                                                                                                                                                               |
| 10:20         | New insights in vitiligo pathogenesis – <b>Invited Speaker: Flora Xiang, Beijing, China</b>                                                                                               |
| 10:40         | miR-2909 impairs Mitochondria – Melanosome crosstalk to restrict melanogenesis through the Klf4 – Mfn2 – NCKX5 Axis – <b>Hitaishi Kaushik, Chandigarh, India</b>                          |
| 10:50         | Circulating and Resident Memory T Cells in Different Stages and Extents of Non Segmental Vitiligo – <b>Iman Sany, Cairo, Egypt</b>                                                        |
| 11:00         | Immune Cell Profiling Reveals Macrophage Dysregulation as a Pathogenic Driver and Therapeutic Target for Vitiligo – <b>Youwen Zhou, Vancouver, Canada</b>                                 |

# Saturday | August 15, 2026

|               |                                                                                                                                                                                                                                                                                                      |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11:10         | Unilateral Peibaldism: presentation of two cases demonstrating a new subtype – <b>Lamia Elgarhy, Tanta, Egypt</b>                                                                                                                                                                                    |
| 11:20         | Glucose Transporter-1 (GLUT-1) Upregulation in Vitiligo: a Possible Link to Skin Depigmentation – <b>Noha Tawfik, Ismailia, Egypt</b>                                                                                                                                                                |
| 11:30         | International League of Dermatological Societies and Global Dermatology – <b>Invited Speaker: Henry W. Lim, Detroit, USA</b>                                                                                                                                                                         |
| 11:50         | Q&A                                                                                                                                                                                                                                                                                                  |
| 12:00 – 13:00 | <b>Satellite Symposium – sponsored by Incyte</b><br>(lunch served)<br><b>Regency D</b><br><b>Advancing Nonsegmental Vitiligo Care: Current Treatment Paradigms, Emerging Therapies, and Case-Based Clinical Insights</b> – Pearl E. Grimes, Los Angeles, USA and Vimal H. Prajapati, Calgary, Canada |
| 13:05 – 13:45 | <b>Session 8 – Keynote Presentation: Ahmed M. Alissa</b><br><b>Regency C</b><br>Chair: Harvey Lui                                                                                                                                                                                                    |
| 13:05         | Introduction – Harvey Lui                                                                                                                                                                                                                                                                            |
| 13:10         | Comprehensive Medical and Surgical Care of Vitiligo: An Integrated Approach – <b>Ahmed M. Alissa, Riyadh, Saudi Arabia</b>                                                                                                                                                                           |
| 13:40         | Q&A                                                                                                                                                                                                                                                                                                  |
| 13:50 – 15:50 | <b>Session 9 – Assessment of Vitiligo Severity, Impact &amp; Therapeutic Response</b><br><b>Regency C</b><br>Chair: Tashmeeta Ahad                                                                                                                                                                   |
| 13:50         | Introduction – Tashmeeta Ahad                                                                                                                                                                                                                                                                        |
| 13:55         | Vitiligo Patient Support Groups – <b>Invited Speaker: Richard Huggins, Detroit, USA</b>                                                                                                                                                                                                              |
| 14:15         | Assessing genetic, phenotypic, and polygenic risk associations of autoimmune comorbidities in FinnGen patients with vitiligo – <b>Iltefat Hamzavi, Detroit, USA</b>                                                                                                                                  |
| 14:25         | Dopamine level in urine and serum of stable non-segmental vitiligo patients before and after excimer light therapy – <b>Reham Abdel Gaber, Assiut, Egypt</b>                                                                                                                                         |
| 14:35         | Prospective registry evaluating narrowband UVB phototherapy in non-segmental vitiligo patients - a study protocol – <b>Marlide Jukema, Amsterdam, Netherlands</b>                                                                                                                                    |
| 14:45         | Patient-Reported Vitiligo Journey, Management, and Stigma in the U.S.: Findings from the National Health and Wellness Survey – <b>Seemal Desai, Dallas, USA</b>                                                                                                                                      |
| 14:55         | Occupational Impairment and Job-Searching Difficulties in Patients with Vitiligo: A Multicenter Cross-Sectional Study – <b>Ju Hee Han, Seoul, Korea</b>                                                                                                                                              |
| 15:05         | Caring through Sharing: Shared Decision-Making in the Treatment of Non-Segmental Vitiligo – A Cross-Cultural Exploratory Survey Study – <b>Sanne Oord, Amsterdam, Netherlands</b>                                                                                                                    |

**Saturday | August 15, 2026**

|                      |                                                                                                                                                                               |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15:15                | Measuring vitiligo in clinical practice: an international consensus study – <b>Marlide Jukema, Amsterdam, Netherlands</b>                                                     |
| 15:25                | Patient-Reported Vitiligo Journey, Management, and Stigma in China: Findings from the National Health and Wellness Survey – <b>Leihong (Flora) Xiang, Beijing, China</b>      |
| 15:35                | Evaluation of Clinical and Dermoscopic Features of Vitiligo Stability with Correlation to Serum Level of CXCL10 in Vitiligo Patient – <b>Lamia Elgarhy, Tanta, Egypt</b>      |
| 15:45                | Q&A                                                                                                                                                                           |
| <b>15:50 – 16:20</b> | <b>BREAK AND POSTER VIEWING IN EXHIBIT HALL</b><br><b>Regency AB</b>                                                                                                          |
| <b>16:20 – 17:40</b> | <b>Session 10 – Phototherapy &amp; Case Reports</b><br><b>Regency C</b><br>Chair: Iltefat Hamzavi                                                                             |
| 16:20                | Introduction – Iltefat Hamzavi                                                                                                                                                |
| 16:25                | Phototherapy in Vitiligo – <b>Invited Speaker: Tasneem F. Mohammad, Detroit, USA</b>                                                                                          |
| 16:45                | 308nm excimer lamp combined infrared light therapy enhances pigment improvement of vitiligo: A retrospective split-body comparative study – <b>Xinxin Li, Hangzhou, China</b> |
| 16:55                | Phototherapy for vitiligo in the era of novel therapies: new combinations and emerging indications – <b>Invited Speaker: Giovanni Leone, Rome, Italy</b>                      |
| 17:15                | Non-invasive multimodal volumetric imaging of vitiligo with subcellular resolution – <b>Zhenguo Wu, Vancouver, Canada</b>                                                     |
| 17:25                | Vitiligo: Challenging Cultural Assumptions and Shaping Identity – <b>Hamna Khuld, Mine Hill, USA</b>                                                                          |
| 17:35                | Q&A                                                                                                                                                                           |
| <b>17:40 – 18:00</b> | <b>VIC7 Closing Comments</b><br><b>Regency C</b>                                                                                                                              |
| <b>18:30 – 21:00</b> | <b>VIC7 CLOSING DINNER</b> (pre-purchased ticket required)<br><b>Prince of Wales</b>                                                                                          |

Sunday | August 16, 2026

07:30 – 09:00 **BREAKFAST**  
*Regency Foyer*

09:00 – 12:00 **Pfizer Canada Advisory Board** (by invitation)  
*Balmoral*



## POSTER LISTING

*As of the date of printing*

### ARTIFICIAL INTELLIGENCE IN VITILIGO

**P.01** Split-Face Comparison of Ruxolitinib versus Tacrolimus in Vitiligo Using Artificial Intelligence-Based Lesion Tracking – *Tahirih Nasser, Toronto, Canada*

### ASSESSMENT OF VITILIGO SEVERITY, IMPACT AND THERAPEUTIC RESPONSE

**P.02** Work and Activity Impairment in Vitiligo Patients: A Multicenter Study – *Ju Hee Han, Seoul, Korea*

**P.03** Relapse of Vitiligo: A Systematic Review and Meta-analysis of Terminology, Definitions, Reported Rates, and Predictors – *Hyun Jeong Ju, Seoul, Korea*

**P.04** Real-World Psychosocial Burden, Quality of Life, and Disease Management of Non-Segmental Vitiligo in the United States – *Samantha Kurosky, New York City, USA*

**P.05** Monitoring Facial Vitiligo Treatment with High-Resolution Noninvasive Skin Imaging – *Mauro Picardo, Rome, Italy*

**P.06** Validity and Feasibility of the Distress Thermometer for Assessing Vitiligo-Related Distress – *Sanne Uientuis, Amsterdam, Netherlands*

**P.07** Development and validation of an Arabic vitiligo impact patient scale short form version – *Mona Atwa, Ismailia, Egypt*

## BASIC SCIENCE

- P.08** Assessment of Vitiligo Activity before and after Alexandrite and Nd:YAG Laser Assisted Hair Removal in Patients with Stable Non Segmental Vitiligo – *Mona Atwa, Ismailia, Egypt*
- P.09** From Stress to Cytotoxicity An Integrative Psychoneuroimmune Model of Vitiligo Pathogenesis – *Nehal Anbar, New Cairo, Egypt*
- P.10** Why is Segmental Vitiligo Different from Non-Segmental Vitiligo? -How can we use this to make Treatments Better for Segmental Vitiligo – *Ajith Cy, Waterloo, Canada*
- P.11** Mannose-Binding Lectin Gene Polymorphism in Vitiligo: an Observational Study and Computational Analysis – *Noha Tawfik, Ismailia, Egypt*

## CASE REPORTS

- P.12** Reticulate acropigmentation of Dohi (Dyschromatosis Symmetrica Hereditaria): A report of two cases – *Lamia Elgarhy, Tanta, Egypt*
- P.13** Long-term Follow-up Analysis of 62 Cases of Hypopigmented Mycosis Fungoides – *Xinxin Li, Hangzhou, China*

## EPIDEMIOLOGY

- P.14** Do Surgical Implants Trigger Autoimmune Depigmentation? A Global Study of Orthopedic and Breast Prostheses – *Racha Cherradi, Houston, USA*
- P.15** Prevalence of Metabolic Syndrome in Mexican Adults With Non-segmental Vitiligo – *Martha Alejandra Morales-Sánchez, Mexico City, Mexico*

## MEDICAL TREATMENT

- P.16** Efficacy of Vitamin C, E, and Ferulic Acid Serum for Managing Post-Excimer Laser Hyperpigmentation in Patients with Facial Vitiligo – *Jung Min Bae, Seoul, Korea*
- P.17** Expert Consensus on the Safety of Aesthetic Procedures in Patients with Vitiligo, an eDelphi Study – *Sheng-Ni Chen, Taoyuan, Taiwan*
- P.18** The efficacy of Topical baricitinib and excimer light in non segmental vitiligo – *Yasmin Elbadrmany, Assuit, Egypt*
- P.19** Vitiligo and Alternative Treatments – *Marwa Khalifa, Tanta, Egypt*
- P.20** Demographics and Baseline Clinical Characteristics of Patients Enrolled in the Phase 3 STOP-V Studies of Pavorcitinib for Nonsegmental Vitiligo – *Deanna Kornacki, Wilmington, USA*
- P.21** Safety of Low-Temperature Argon Plasma in the Treatment of Non-Segmental Vitiligo – *Nader Ouaili, Moscow, Russia*
- P.22** Intralesional Methotrexate in Localized Vitiligo Experience from tertiary care centre in India – *Mona Sharma, Delhi, India*
- P.23** Fractional CO<sub>2</sub> laser-assisted delivery of stem cell-derived exosomes in stable vitiligo resistant to standard therapy a retrospective randomized controlled cohort – *Aseem Sharma, Mumbai, India*
- P.24** Topical Ruxolitinib and Latanoprost for Vitiligo: Real-World Data From Latin-American Patients—A Case Series – *Keren Tovar-Silos, Guadalajara, Mexico*

- P.25** Rapid re-pigmentation of facial non-segmental vitiligo with oral Upadacitinib and NB-UVB phototherapy combination therapy – **Xin-gang Wu, Hangzhou, China**

## PHOTOTHERAPY

- P.26** Extended Phototherapy Sessions and Their Effect on Serum Beta-Endorphin and Well-Being in Vitiligo Patients – **Wedad Mosataf, Cairo, Egypt**
- P.27** Efficacy of The Combination of Excimer Light and Microneedling either with Pentoxifylline or with 5-fluorouracil in Treatment of Vitiligo, A comparative Study – **Nada Yousef, Cairo, Egypt**
- P.28** Autofluorescence Biomarkers of Vitiligo Detected by Non-invasive in vivo Excitation-Emission Matrix Spectroscopy – **Jianhua Zhao, Vancouver, Canada**
- P.29** *Poster withdrawn*

## SURGICAL TREATMENT

- P.30** *Poster withdrawn*
- P.31** Repigmentation by Reverse Koebner Phenomenon in a Vitiligo patients treated with Topical Application of TCA 80% – **Ahmed Abdallah, Kafr Elsheikh, Egypt**
- P.32** Low-Cost Modified Jodhpur Technique Using Manual Manekshaw Dermabrader and Sterile Polyethylene Dressing Layer in the Treatment of Stable Vitiligo – **Ahmed Abdallah, Kafr Elsheikh, Egypt**
- P.33** The role of mini-oral pulse steroid therapy in melanocyte keratinocyte transplantation: A randomized controlled trial – **Sherouk Elessawy, Cairo, Egypt**
- P.34** Cadaver-Based Simulation for Comprehensive Hands-on Training in Vitiligo Surgery: A High-Volume Scalable Model – **Deepti Ghia, Mumbai, India**
- P.35** *Poster withdrawn*
- P.36** Office-Based Procedural Approaches in Vitiligo – **Hagar Nofal, Cairo, Egypt**
- P.37** Excimer Light priming of donor site prior to Non-Cultured Epidermal Cell Suspension Grafting preliminary results of controlled clinical trial – **Hagar Nofal, Cairo, Egypt**
- P.38** Clinical Outcomes of Autologous Melanocyte Transplantation in Segmental Vitiligo, Fitzpatrick Skin Type III – **Botir Saatov, Tashkent, Uzbekistan**
- P.39** Trypsinized Split-thickness Grafting A Novel Technique for Improving Surgical Outcomes in Vitiligo – **Aseem Sharma, Mumbai, India**
- P.40** Resistent Vitiligo patches treated with Fractional Co2 as add on with existing medical treatment – **Mahesh Unni, Latur, India**

## TRANSLATIONAL RESEARCH

- P.41** Study of Interleukin-15 immunoexpression in the skin of vitiligo patients – **Lamia Elgarhy, Tanta, Egypt**
- P.42** Application of Exposure-Response Modeling to Inform the Phase 3 Dose Selection of Povorcitinib in Nonsegmental Vitiligo – **Jessica Wojciechowski, Wilmington, USA**

## SPONSOR PROFILES

### abbvie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience—and products and services in our Allergan Aesthetics portfolio. Dermatology is a key area of research, with a focus on psoriasis, psoriatic arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, and alopecia areata. With more than 25 years of immunology experience, our products have been used to treat more than 1 million patients worldwide. We have manufacturing and/or R&D facilities in approximately 20 countries to support access globally. Learn more at [www.abbvie.com](http://www.abbvie.com). For healthcare professionals only. ©2025 AbbVie. ALL RIGHTS RESERVED

#### IMAGING EXCELLENCE FROM



Canfield Scientific is the global leader providing custom skin imaging systems and services for pharmaceutical, biotech, and medical device companies to demonstrate efficacy in clinical trials worldwide. Canfield's patented technology includes multi-spectral and multi-modal 2D and 3D imaging systems, cloud-based digital asset management, and applications for objective analysis within compliant and validated systems. ISO 27001 certification confirms Canfield's Information Security Management System meets the highest international standards.



Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

For additional information on Incyte, please visit [Incyte.com](http://Incyte.com) and follow @Incyte on Twitter. For more information on OPZELURA™ (ruxolitinib) cream 1.5%, visit [OpzeluraHCP.com](http://OpzeluraHCP.com).



#### Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at [www.Pfizer.com](http://www.Pfizer.com). In addition, to learn more, please visit us on [www.Pfizer.com](http://www.Pfizer.com) and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://Facebook.com/Pfizer).



For more information, visit the website at [www.takeda.com](http://www.takeda.com).



# Incyte Dermatology

## INSPIRE CHANGE

MEANINGFUL CHANGE TAKES REAL EFFORT. With deep roots in immunology and a science-first approach, Incyte is tirelessly innovating and actively listening to you as change-makers to help you positively impact the lives of patients, one Dermatology solution at a time.

Incyte and Incyte logo are registered trademarks of Incyte.  
©2025-2026, Incyte Biosciences Canada Corporation.





*Victory over  
Vitiligo in  
Vancouver*

**CONGRESS SECRETARIAT**  
Simply Eventful Mangement, Inc  
Vancouver, Canada  
E: [info@simplyeventful.com](mailto:info@simplyeventful.com)  
W: [www.simplyeventful.com](http://www.simplyeventful.com)